BioCentury
ARTICLE | Company News

BioMotiv, Rutgers launch TamRx

February 8, 2019 1:52 AM UTC

Cancer immunotherapy company TamRx LLC (Cleveland, Ohio) launched Feb. 7 from pharmaceutical accelerator BioMotiv LLC (Cleveland, Ohio), shooting to reach the clinic with its pan-TAM inhibitors in 2021.

The company is based on research from Rutgers University, which also has an undisclosed stake in TamRx...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article